{
    "clinical_study": {
        "@rank": "136029", 
        "brief_summary": {
            "textblock": "-  Title: Open-label, prospective exploratory study to assess the effects of the\n           AlphaCore\u00ae device on central and peripheral airway dimensions in patients with COPD.\n\n        -  Indication:  COPD patients\n\n        -  Study Design: Open-label, prospective design\n\n        -  Study Phase:  II\n\n        -  Test treatment duration: 1 day\n\n        -  Test treatment: AlphaCore\u00ae device\n\n        -  Dosage regimen: 1 session of stimulation during 90 seconds\n\n        -  Patient number: up to 10 evaluable patients with COPD\n\n        -  Patient age: \u2265 18 years\n\n        -  Sex: male or female\n\n        -  Primary objective: The evaluation of the effect of the AlphaCore\u00ae device on central and\n           peripheral airway dimensions with Computational Fluid Dynamics (CFD).\n\n        -  Secondary objectives: The assessment of the effect of the AlphaCore\u00ae device on lung\n           function (spirometry, diffusion and resistance) and on patient reported outcomes\n           (PRO`s)."
        }, 
        "brief_title": "Prospective Exploratory Study to Assess the Effects of the AlphaCore\u00ae Device in Patients With COPD", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": "Pulmonary Disease, Chronic Obstructive"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a documented diagnosis of COPD\n\n          -  Male or female patients aged \u226518 years\n\n          -  Patients with a co-operative attitude to be treated with the AlphaCore\u00ae device\n\n          -  Patients should take anti-cholinergics\n\n          -  Female patient of childbearing potential who confirm to use a contraception method\n             during the study\n\n          -  Written informed consent obtained\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating females or females at risk of pregnancy at screening and not\n             willing to use an appropriate contraception method during the study period\n\n          -  Inability to carry out pulmonary function testing\n\n          -  Patients with an uncontrolled disease or any condition that might, in the judgement\n             of the investigator, place the patient at undue risk or potentially compromise the\n             results or interpretation of the study\n\n          -  Patients with an electrical and/or neurostimulator device (e.g. a cardiac pacemaker,\n             a vagal neurostimulator, a defibrillator, a cochlear implant, \u2026)\n\n          -  Patients with an abscess or other infection or lesion (incl. lymphadenopathy) at the\n             therapy head placement site\n\n          -  Patients with a compromised cervical anatomy (such as from scaring, infection or\n             suspected carotid artery disease) or a cervical vagotomy\n\n          -  Patients with a history of carotid endarterectomy or vascular neck surgery on the\n             right side\n\n          -  Patients with coagulopathy, irregular heart rhythm or that are on pressor medication\n\n          -  Patients unlikely to comply with the protocol or unable to understand the nature,\n             scope and possible consequences of the study\n\n          -  Patients who received any investigational new drug within the last 4 weeks prior to\n             the screening visit\n\n          -  Patients treated with any non-permitted concomitant medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720680", 
            "org_study_id": "PML_DOC_1202"
        }, 
        "intervention": [
            {
                "description": "All patients will have 2 low dose multi-slice CT's at visit 2: one CT \"pre-dose\" and one CT 1 to 3 hours \"post-dose\".", 
                "intervention_name": "Low dose multislice CT thorax", 
                "intervention_type": "Radiation"
            }, 
            {
                "description": "All patients will receive a stimulation therapy of 90 seconds delivered by the AlphaCore.", 
                "intervention_name": "AlphaCore\u00ae device", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "Functional Imaging", 
            "Patient Reported Outcome (PRO)", 
            "Lung Function", 
            "AlphaCore", 
            "Computational Fluid Dynamics"
        ], 
        "lastchanged_date": "June 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Edegem", 
                    "country": "Belgium", 
                    "state": "Antwerp", 
                    "zip": "2650"
                }, 
                "name": "University Hospital Antwerp"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open-label, Prospective Exploratory Study to Assess the Effects of the AlphaCore\u00ae Device on Central and Peripheral Airway Dimensions in Patients With COPD", 
        "overall_official": {
            "affiliation": "University Hospital, Antwerp", 
            "last_name": "Wilfried De Backer, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to evaluate the effect of the AlphaCore\u00ae on central and peripheral airway dimensions with functional imaging using airway segmentation and computational methods (CFD).", 
            "measure": "Changes in functional imaging parameters", 
            "safety_issue": "No", 
            "time_frame": "At V2 (2 - 14 days after screening) pre and post treatment with the AlphaCore device"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720680"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital, Antwerp", 
            "investigator_full_name": "Wilfried De Backer", 
            "investigator_title": "Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The secondary objectives of this study are to assess the effects after treatment with the AlphaCore\u00ae on lung function (spirometry, resistance and diffusion), on COPD Assessment Test (CAT), on Modified Medical Research Council (MMRC), on Saint George`s Respiratory Questionnaire (SGRQ) and on health questionnaire EQ-5D-5L.", 
                "measure": "Changes in lung function parameters", 
                "safety_issue": "No", 
                "time_frame": "At V2 (2 - 14 days after screening) pre and post treatment with the AlphaCore device"
            }, 
            {
                "description": "The secondary objectives of this study are to assess the effects after treatment with the AlphaCore\u00ae on lung function (spirometry, resistance and diffusion), on COPD Assessment Test (CAT), on Modified Medical Research Council (MMRC), on Saint George`s Respiratory Questionnaire (SGRQ) and on health questionnaire EQ-5D-5L.", 
                "measure": "Changes in patient reports outcomes (PROs)", 
                "safety_issue": "No", 
                "time_frame": "At V2 before treatment with the AlphaCore device and at follow-up visit (14 days after visit 2)"
            }
        ], 
        "source": "University Hospital, Antwerp", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Antwerp", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}